Mesoblast Sees Major Change in Substantial Holding
Mesoblast Limited (AU:MSB) has released an update.Don't Miss Our Christmas Offers:Discover the latest stocks recommended by top Wall Street ...
FiercePharma8d
After two rejections, FDA approves Mesoblast's first-of-its-kind cell therapy
More than four years later—and after two rejections from the agency—Mesoblast has finally gained an endorsement from the U.S.
Mesoblast has received FDA approval for its drug Ryoncil
Mesoblast shareholders are sitting on as much as 10-fold gains for the year, after the US Food and Drug Administration ...
Mesoblast Finally Gets Its Approval In GVHD: Where Now?
Investment risks and competition challenge Mesoblast Limited's recent approval for Remestemcel-L in treating ...
Stockhead on MSN9d
Health Check: Joy as Mesoblast wins its first FDA approval for a stem-cell therapy after decades of trying
After years of trying, Mesoblast has won US FDA approval for its stem-cell therapies to treat the fatal graft-versus-host ...
Hosted on MSN4d
Jefferies Downgrades Mesoblast Limited - Depositary Receipt () (MESO)
Fintel reports that on December 23, 2024, Jefferies downgraded their outlook for Mesoblast Limited - Depositary Receipt () ...
US FDA approves Mesoblast's cell therapy for graft-versus-host disease
The U.S. Food and Drug Administration on Wednesday approved Mesoblast's cell therapy for treating a type of complication that ...
Why the Mesoblast share price is diving 18% after an FDA win
The Mesoblast Ltd (ASX: MSB) share price is taking a dive today. Here’s why the biotech stock is under pressure after ...
Mesoblast downgraded to Hold from Buy at Jefferies
Jefferies downgraded Mesoblast (MESO) to Hold from Buy with a price target of A$2.30, up from A$1.10. The firm updated the company’s for the ...
Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges
Mesoblast's Ryoncil is now FDA-approved for pediatric SR-aGvHD, marking a milestone in mesenchymal stromal cell therapies in ...
Mesoblast to be Added to Nasdaq Biotechnology Index
NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its upcoming addition to the Nasdaq ...